Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice

Pharmaceutical Research

Volumn 17, Issue 2, 2000, Pages 205-215

  Chiou, Win L ^a   Chung, Sang M ^a   Wu, Ta C ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Bioavailability; Drag absorption; Mice; P glycoprotein; Tacrolimus

Indexed keywords

GLYCOPROTEIN P; TACROLIMUS; TALINOLOL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG METABOLISM; FIRST PASS EFFECT; GASTROINTESTINAL ABSORPTION; KNOCKOUT MOUSE; LIVER METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; TACROLIMUS;

EID: 0034018290     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007573531947     Document Type: Article

References (17)

1. 1. K. Yokogawa, M. Takahashi, I. Tamai, H. Konishi, M. Nomura, S. Moritani, K. Miyamoto, and A. Tsuji. P-glycoprotein-dependent disposition kinetics of Tacrolimus: Studies in mdr la Knockout Mice. Pharm. Res. 16:1213-1218 (1999).
2. 2. M. Gibaldi and D. Perrier. Pharmacokinetics, Dekker. New York, 1982
3. 3. W. L. Chiou. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokin. Biopharm. 6:539-546 (1978).
4. 4. K. Takada, H. Usuda, M. Oh-Hashi, H. Yoshikawa, S. Muranishi, and H. Tanaka. Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. J. Pharmacobio-Dyn. 14:34-42 (1991).
5. 5. G. R. Wilkinson and D. G. Shand. A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18:377-390 (1975).
6. 6. B. Davies and T. Morris. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095 (1993).
7. 7. W. L. Chiou. New compartment-and model-independent method for rapid calculation of drug absorption rates. J. Pharm. Sci. 69:57-62 (1980).
8. 8. F. H. Hsu, T. Prueksaritanont, M. G. Lee, and W. L. Chiou. The phenomenon and cause of the dose-dependent oral absorption of chlorothiazide in rats: extrapolation to human data based on the body surface area concept. J. Pharmacokin. Biopharm. 15:369-86 (1987).
9. 9. W. J. Jusko, W. Piekoszewski, G. B. Klintmalm, M. S. Shaefer, M. F. Hebert, A. A. Piergies, C. C. Lee, P. Schechter, and Q. A. Mekki. Pharmacokinetics of tacrolimus in liver transplant patients. Clin. Pharmacol. Ther. 57:281-290 (1995).
10. 10. W. L. Chiou. New perspectives on the theory of permeability and resistance in the study of drug transport and absorption. J. Pharmacokin. Biopharm. 24:433-42 (1996).
11. 11. T. Honbo, M. Kobayashi, K. Hane, T. Hata, and Y. Ueda. The oral dosage form of FK-506. Transplant. Proc. 19(Suppl. 6): 17-22 (1987).
12. 12. W. L. Chiou and A. Barve. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm. Res. 15:1792-1795 (1998).
13. 13. W. L. Chiou, H. Y. Jeong, S. M. Chung, and T. C. Wu. Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm. Res. 17:135-140 (2000).
14. 14. U. Wetterich, H. Spahn-Langguth, E. Mutschler, B. Terhaag, W. Rösch, and P. Langguth. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: Concentration-and dose-dependent absorption in vitro and in vivo. Pharm. Res. 13:514-522 (1996)
15. 15. M. Naito, T. Oh-hara, A. Yamazaki, T. Danki, and T. Tsuruo. Reversal of multidrug resistance by an immunosuppressive agent FK-506. Cancer Chemother. Pharmacol. 29:195-200 (1992)
16. 16. A. H. Schinkel, U. Mayer, E. Wagenaar, C. A. A. M. Mol, L. van Deemter, J. J. M. Smit, M. A. van der Valk, A. C. Voordouw, H. Spits, O. van Tellingen, J. M. J. M. Zijlmans, W. E. Fibbe, and P. Borst. Normal viability and altered pharmacokinetics in mice lacking mdr la (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U.S.A. 94:4028-4033 (1997)
17. 17. W. L. Chiou and S. Ríegelman. Disposition kinetics of griseofulvin in dogs. J. Pharm. Sci. 58:1500-1504 (1969)